肺癌放射免疫新实践

doi:10.6040/j.issn.1671-7554.0.2021.0949

摘要/Abstract

摘要： 近年来,放疗联合免疫治疗(iRT)引起了肿瘤学界的强烈关注,目前有数百项关于iRT的大型临床试验在进行。放疗会使肿瘤细胞发生免疫原性死亡,促进肿瘤抗原释放、提呈,激活T细胞;放疗也可以重塑肿瘤微环境,使其从免疫抑制状态转变为免疫激活状态。免疫检查点抑制剂不仅能解除T细胞抑制,而且能使肿瘤血管正常化,从而改善肿瘤微环境缺氧,增加放疗敏感性,这就是放疗与免疫治疗协同抗肿瘤的基本原理。iRT日趋成熟,但也面临着诸多挑战。本文分别回顾免疫治疗和放疗近年来的发展历程,并探讨iRT使用的时机、分割剂量、治疗相关毒性反应等。

关键词: 肺癌, 放射治疗, 免疫治疗, 免疫检查点抑制剂

Abstract: In recent years, immunotherapy combined with radiotherapy(iRT)has attracted great attention in the field of oncology, and hundreds of large clinical trials on iRT are currently underway. Radiotherapy can cause immunogenic death of tumor cells, promote the release and presentation of tumor antigens, and activate T cells. Radiotherapy can also reshape the tumor microenvironment from immunosuppression to immune activation. Immune checkpoint inhibitors can not only relieve T cell inhibition but also normalize tumor vessels so as to improve tumor hypoxia and increase radiosensitivity, which is the basic principle of synergistic anti-tumor effect of radiotherapy and immunity. Now iRT is becoming more and more mature, but it also faces many challenges. This paper will review the development of immunotherapy and radiotherapy in recent years, and explore the timing, fractional dose and treatment-related toxicity of iRT.

Key words: Lung cancer, Radiotherapy, Immunotherapy, Immune checkpoint inhibitors

中图分类号:

R734.2

于金明,颜薇薇,陈大卫. 肺癌放射免疫新实践[J]. 山东大学学报 (医学版), 2021, 59(9): 1-8.

YU Jinming, YAN Weiwei, CHEN Dawei. New practice of radio-immunotherapy for lung cancer[J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 1-8.

参考文献

[1] Matsushita H, Vesely MD, Koboldt DC, et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting [J]. Nature, 2012, 482(7385): 400-404.
[2] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation [J]. Cell, 2011, 144(5): 646-674.
[3] Roentgen WC. On a new kind of ray(first report)[J]. Munch Med Wochenschr, 1959, 101: 1237-1239.
[4] Thariat J, Hannoun-Levi JM, Sun Myint A, et al. Past, present, and future of radiotherapy for the benefit of patients [J]. Nat Rev Clin Oncol, 2013, 10(1): 52-60.
[5] Ross GM. Induction of cell death by radiotherapy [J]. Endocr Relat Cancer, 1999, 6(1): 41-44.
[6] Mole RH. Whole body irradiation; radiobiology or medicine?[J]. Br J Radiol, 1953, 26(305): 234-241.
[7] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[8] 郑荣寿, 孙可欣, 张思维,等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1): 19-28. ZHENG Rongshou, SUN Kexin, ZHANG Siwei, et al. Report of cancer epidemiology in China, 2015 [J]. Chinese Journal of Oncology, 2019, 41(1): 19-28.
[9] Weiner LM. Cancer immunotherapy—the endgame begins [J]. N Engl J Med, 2008, 358(25): 2664-2665.
[10] Jacob Bickels, Yehuda Kollender, Ofer Merinsky, et al. Coleys toxin: historical perspective [J]. Isr Med Assoc J, 2002, 4(6): 471-472.
[11] Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy [J]. Science, 2013, 342(6165): 1432-1433.
[12] Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade [J]. Science, 2018, 359(6382): 1350-1355.
[13] Guo ZS. The 2018 Nobel Prize in medicine goes to cancer immunotherapy(editorial for BMC cancer)[J]. BMC Cancer, 2018, 18(1): 1086. doi: 10.1186/s12885-018-5020-3.
[14] Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer [J]. N Engl J Med, 2018, 379(21): 2040-2051.
[15] Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer [J]. N Engl J Med, 2018, 378(22): 2078-2092.
[16] Reck M, Rodriguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater [J]. J Clin Oncol, 2019, 37(7): 537-546.
[17] Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer(KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial [J]. Lancet, 2019, 393(10183): 1819-1830.
[18] Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC [J]. N Engl J Med, 2018, 378(24): 2288-2301.
[19] Horn L, Mansfield AS, Szczesna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-sell lung cancer [J]. N Engl J Med, 2018, 379(23): 2220-2229.
[20] Goldman JW, Garassino MC, Chen Y, et al. Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer(CASPIAN): a randomized, controlled, open-label, phase III study [J]. Lung Cancer, 2020, 149: 46-52. doi: 10.1016/j.lungcan.2020.09.003.
[21] Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study [J]. J Clin Oncol, 2020, 38(1): 1-10.
[22] Gettinger S, Horn L, Jackman D, et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study [J]. J Clin Oncol, 2018, 36(17): 1675-1684.
[23] Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced non?small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study [J]. J Clin Oncol, 2019, 37(28): 2518-2527.
[24] Xu-Monette ZY, Zhou J, Young KH. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas [J]. Blood, 2018, 131(1): 68-83.
[25] Tsai KK, Zarzoso I, Daud AI. PD-1 and PD-L1 antibodies for melanoma [J]. Hum Vaccin Immunother, 2014, 10(11): 3111-3116.
[26] Oliveira AF, Bretes L, Furtado I. Review of PD-1/PD-L1 inhibitors in metastatic dMMR/MSI-H colorectal cancer [J]. Front Oncol, 2019, 9: 396. doi: 10.3389/fonc.2019.00396.
[27] Smit EF, de Langen AJ. Pembrolizumab for all PD-L1-positive NSCLC [J]. Lancet, 2019, 393(10183): 1776-1778.
[28] Herrera FG, Bourhis J, Coukos G. Radiotherapy combination opportunities leveraging immunity for the next oncology practice [J]. CA Cancer J Clin, 2017, 67(1): 65-85.
[29] Forster MD, Devlin MJ. Immune checkpoint inhibition in head and neck cancer [J]. Front Oncol, 2018, 8: 310. doi: 10.3389/fonc.2018.00310.
[30] Motz GT, Coukos G. Deciphering and reversing tumor immune suppression [J]. Immunity, 2013, 39(1): 61-73.
[31] Scheper W, Kelderman S, Fanchi LF, et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers [J]. Nat Med, 2019, 25(1): 89-94.
[32] Jaffray DA. Image-guided radiotherapy: from current concept to future perspectives [J]. Nat Rev Clin Oncol, 2012, 9(12): 688-699.
[33] Kirkpatrick JP, Kelsey CR, Palta M, et al. Stereotactic body radiotherapy: a critical review for nonradiation oncologists[J]. Cancer, 2014, 120(7): 942-954.
[34] Brooks ED, Sun B, Feng L, et al. Association of long-term outcomes and survival with multidisciplinary salvage treatment for local and regional recurrence after stereotactic ablative radiotherapy for early-stage lung cancer [J]. JAMA Netw Open, 2018, 1(4): e181390. doi: 10.1001/jamanetworkopen.
[35] Bernstein MB, Krishnan S, Hodge JW,et al. Immunotherapy and stereotactic ablative radiotherapy(ISABR): a curative approach? [J]. Nat Rev Clin Oncol, 2016, 13(8): 516-524.
[36] Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC [J]. N Engl J Med, 2018, 379(24): 2342-2350.
[37] Stevens R, Macbeth F, Toy E, et al. Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer [J]. Cochrane Database Syst Rev, 2015, 1: CD002143. doi: 10.1002/14651858.
[38] Ribatti D, Mangialardi G, Vacca A. Stephen paget and the ‘seed and soil’ theory of metastatic dissemination [J]. Clin Exp Med, 2006, 6(4): 145-149.
[39] Deng L, Liang H, Burnette B, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice [J]. J Clin Invest, 2014, 124(2): 687-695.
[40] Dovedi SJ, Adlard AL, Lipowska-Bhalla G, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade [J]. Cancer Res, 2014, 74(19): 5458-5468.
[41] Garon EB, Rizvi NA, Hui RN, et al. Pembrolizumab for the treatment of non-small-cell lung cancer [J]. N Engl J Med, 2015, 372(21): 2018-2028.
[42] Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer [J]. N Engl J Med, 2015, 373(17): 1627-1639.
[43] Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer [J]. N Engl J Med, 2016, 375(19): 1823-1833.
[44] Theelen W, Chen D, Verma V, et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials [J]. Lancet Respir Med, 2021, 9(5): 467-475.
[45] Theelen W, Peulen HMU, Lalezari F, et al. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial [J]. JAMA Oncol, 2019, 5(9): 1276-1282.
[46] Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced nonsmall-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study [J]. J Clin Oncol, 2019, 37(28): 2518-2527.
[47] Welsh J, Menon H, Chen D, et al. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial [J]. J Immunother Cancer, 2020, 8(2):e001001. doi: 10.1136/jitc-2020-001001.
[48] Formenti SC, Demaria S. Radiation therapy to convert the tumor into an in situ vaccine [J]. Int J Radiat Oncol Biol Phys, 2012, 84(4): 879-880.
[49] Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8⁺ T cells: changing strategies for cancer treatment [J]. Blood, 2009, 114(3): 589-595.
[50] 张强, 吴邵雅, 张靖. 放疗对肿瘤微环境的重塑及增强免疫治疗疗效机制的研究进展 [J]. 肿瘤防治研究, 2021, 48(1): 1-6. ZHANG Qiang, WU Shaoya, ZHANG Jing. New insight on tumor microenvironment remodelling and augmented therapeutic efficacy of immunotherapy by radiotherapy [J]. Cancer Research on Prevention and Treatment, 2021, 48(1): 1-6.
[51] Deng L, Liang H, Xu M, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors [J]. Immunity, 2014, 41(5): 843-852.
[52] Woo SR, Fuertes MB, Corrales L, et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors [J]. Immunity, 2014, 41(5): 830-842.
[53] Klug F, Prakash H, Huber PE, et al. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy [J]. Cancer Cell, 2013, 24(5): 589-602.
[54] Demaria S, Coleman CN, Formenti SC. Radiotherapy: changing the game in immunotherapy [J]. Trends Cancer, 2016, 2(6): 286-294.
[55] Dillon MT, Bergerhoff KF, Pedersen M, et al. ATR inhibition potentiates the radiation-induced inflammatory tumor microenvironment [J]. Clin Cancer Res, 2019, 25(11): 3392-3403.
[56] Wang Y, Liu ZG, Yuan H, et al. The Reciprocity between radiotherapy and cancer immunotherapy [J]. Clin Cancer Res, 2019, 25(6): 1709-1717.
[57] Vanpouille-Box C, Alard A, Aryankalayil MJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity [J]. Nat Commun, 2017, 8: 15618. doi: 10.1038/ncomms15618.
[58] Buchwald ZS, Wynne J, Nasti TH, et al. Radiation, immune checkpoint blockade and the abscopal effect: a critical review on timing, dose and fractionation [J]. Front Oncol, 2018, 8: 612. doi: 10.3389/fonc.2018.00612.
[59] Chen D, Patel RR, Verma V, et al. Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy [J]. Radiother Oncol, 2020, 150: 114-120. doi: 10.1016/j.radonc.
[60] Brooks ED, Chang JY. Time to abandon single-site irradiation for inducing abscopal effects [J]. Nat Rev Clin Oncol, 2019, 16(2): 123-135.
[61] Huang Y, Snuderl M, Jain RK. Polarization of tumor-associated macrophages: a novel strategy for vascular normalization and antitumor immunity [J]. Cancer Cell, 2011, 19(1): 1-2.
[62] Shin SC, Lee KM, Kang YM, et al. Alteration of cytokine profiles in mice exposed to chronic low-dose ionizing radiation [J]. Biochem Biophys Res Commun, 2010, 397(4): 644-649.
[63] Ina Y, Sakai K. Activation of immunological network by chronic low-dose-rate irradiation in wild-type mouse strains: analysis of immune cell populations and surface molecules [J]. Int J Radiat Biol, 2005, 81(10): 721-729.
[64] Barsoumian H, Cushman TR, Caetano MDS, et al. Low dose radiation improves anti-tumor responses in a phase 2 prospective trial of concurrent or sequential stereotactic radiation and ipilimumab in patients with metastatic lesions[J]. International Journal of Radiation Oncology Biology Physics, 2018, 102(3): S26-S26.
[65] Arnold KM, Flynn NJ, Raben A, et al. The impact of radiation on the tumor microenvironment: effect of dose and fractionation schedules [J]. Cancer Growth Metastasis, 2018, 11:1 179064418761639. doi: 10.1177/1179064418761639.
[66] Yang H, Jin T, Li M,et al. Synergistic effect of immunotherapy and radiotherapy in non-small cell lung cancer: current clinical trials and prospective challenges [J]. Precision Clinical Medicine, 2019, 2(1): 57-70.
[67] Bang A, Schoenfeld JD. Immunotherapy and radiotherapy for metastatic cancers [J]. Ann Palliat Med, 2019, 8(3): 312-325.
[68] Luke JJ, Lemons JM, Karrison TG, et al. Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors [J]. J Clin Oncol, 2018, 36(16): 1611-1618.
[69] Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer [J]. N Engl J Med, 2017, 377(20): 1919-1929.
[70] Bang A, Wilhite TJ, Pike LRG, et al. Multicenter evaluation of the tolerability of combined treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiation therapy [J]. Int J Radiat Oncol Biol Phys, 2017, 98(2): 344-351.
[71] Durm GA, Jabbour SK, Althouse SK, et al. A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179 [J]. Cancer, 2020, 126(19): 4353-4361.
[72] McCusker MG, Scilla KA, Simone CB, et al. Proton beam therapy and immune checkpoint inhibitors in malignant pleural mesothelioma [J]. J Thorac Oncol, 2019, 14(9): e185-e187.
[73] Shibaki R, Akamatsu H, Fujimoto M, et al. Nivolumab induced radiation recall pneumonitis after two years of radiotherapy [J]. Ann Oncol, 2017, 28(6): 1404-1405.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed